ID   A2780/CP70
AC   CVCL_0135
SY   A2780/cp70; A2780 CP70; A2780(CP70); A2780CP70; A2780/CP; A2780-CP; A2780-cp; A 2780 CP; A2780CP; 2780CP; CP70; CP-70
DR   BTO; BTO:0003845
DR   MCCL; MCC:0000028
DR   cancercelllines; CVCL_0135
DR   GEO; GSM184400
DR   GEO; GSM184401
DR   GEO; GSM743511
DR   GEO; GSM851908
DR   GEO; GSM1178064
DR   GEO; GSM1178065
DR   NCBI_Iran; C454
DR   PRIDE; PXD003668
DR   Progenetix; CVCL_0135
DR   Wikidata; Q54606604
RX   PubMed=1348364;
RX   PubMed=1999494;
RX   PubMed=2429947;
RX   PubMed=3335022;
RX   PubMed=3539322;
RX   PubMed=7954422;
RX   PubMed=9554442;
RX   PubMed=12080474;
RX   PubMed=17254797;
RX   PubMed=19926575;
RX   PubMed=27561551;
RX   PubMed=28196595;
RX   PubMed=28546799;
WW   https://tcpaportal.org/mclp/
CC   Part of: MD Anderson Cell Lines Project.
CC   Population: African American.
CC   Selected for resistance to: ChEBI; CHEBI:27899; Cisplatin (CDDP).
CC   Sequence variation: Mutation; HGNC; 795; ATM; Simple; p.Pro604Ser (c.1810C>T); ClinVar=VCV000127343; Zygosity=Unspecified (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Lys128_Arg130del (c.383_391del9); Zygosity=Unspecified (from parent cell line).
CC   Omics: Deep proteome analysis.
CC   Omics: N-glycan profiling by lectin array.
CC   Omics: Protein expression by reverse-phase protein arrays.
CC   Omics: Transcriptome analysis by microarray.
CC   Derived from site: In situ; Ovary; UBERON=UBERON_0000992.
ST   Source(s): PubMed=17254797
ST   Amelogenin: X
ST   CSF1PO: 11
ST   D13S317: 13
ST   D16S539: 11,13
ST   D18S51: 16,18
ST   D21S11: 27,28
ST   D3S1358: 14,16
ST   D5S818: 11,12
ST   D7S820: 9,10
ST   D8S1179: 15,17
ST   FGA: 19,24
ST   TH01: 6
ST   TPOX: 8,10
ST   vWA: 15,16
DI   NCIt; C7979; Ovarian endometrioid adenocarcinoma
DI   ORDO; Orphanet_454723; Endometrioid carcinoma of ovary
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_0134 ! A2780
SX   Female
AG   Age unspecified
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 05-10-23; Version: 28
//
RX   PubMed=1348364; DOI=10.1073/pnas.89.7.3070;
RA   Godwin A.K., Meister A., O'Dwyer P.J., Huang C.-S., Hamilton T.C.,
RA   Anderson M.E.;
RT   "High resistance to cisplatin in human ovarian cancer cell lines is
RT   associated with marked increase of glutathione synthesis.";
RL   Proc. Natl. Acad. Sci. U.S.A. 89:3070-3074(1992).
//
RX   PubMed=1999494; DOI=10.1172/JCI115080;
RA   Parker R.J., Eastman A., Bostick-Bruton F., Reed E.;
RT   "Acquired cisplatin resistance in human ovarian cancer cells is
RT   associated with enhanced repair of cisplatin-DNA lesions and reduced
RT   drug accumulation.";
RL   J. Clin. Invest. 87:772-777(1991).
//
RX   PubMed=2429947; DOI=10.20772/cancersci1985.77.9_941;
RA   Tsuruo T., Hamilton T.C., Louie K.G., Behrens B.C., Young R.C.,
RA   Ozols R.F.;
RT   "Collateral susceptibility of adriamycin-, melphalan- and
RT   cisplatin-resistant human ovarian tumor cells to bleomycin.";
RL   Jpn. J. Cancer Res. 77:941-945(1986).
//
RX   PubMed=3335022;
RA   Alley M.C., Scudiero D.A., Monks A., Hursey M.L., Czerwinski M.J.,
RA   Fine D.L., Abbott B.J., Mayo J.G., Shoemaker R.H., Boyd M.R.;
RT   "Feasibility of drug screening with panels of human tumor cell lines
RT   using a microculture tetrazolium assay.";
RL   Cancer Res. 48:589-601(1988).
//
RX   PubMed=3539322;
RA   Behrens B.C., Hamilton T.C., Masuda H., Grotzinger K.R.,
RA   Whang-Peng J., Louie K.G., Knutsen T., McKoy W.M., Young R.C.,
RA   Ozols R.F.;
RT   "Characterization of a cis-diamminedichloroplatinum(II)-resistant
RT   human ovarian cancer cell line and its use in evaluation of platinum
RT   analogues.";
RL   Cancer Res. 47:414-418(1987).
//
RX   PubMed=7954422;
RA   Johnson S.W., Swiggard P.A., Handel L.M., Brennan J.M., Godwin A.K.,
RA   Ozols R.F., Hamilton T.C.;
RT   "Relationship between platinum-DNA adduct formation and removal and
RT   cisplatin cytotoxicity in cisplatin-sensitive and -resistant human
RT   ovarian cancer cells.";
RL   Cancer Res. 54:5911-5916(1994).
//
RX   PubMed=9554442; DOI=10.1093/jnci/90.8.597;
RA   Sabichi A.L., Hendricks D.T., Bober M.A., Birrer M.J.;
RT   "Retinoic acid receptor beta expression and growth inhibition of
RT   gynecologic cancer cells by the synthetic retinoid N-(4-hydroxyphenyl)
RT   retinamide.";
RL   J. Natl. Cancer Inst. 90:597-605(1998).
//
RX   PubMed=12080474; DOI=10.1038/sj.onc.1205542;
RA   Manzano R.G., Montuenga L.M., Dayton M., Dent P., Kinoshita I.,
RA   Vicent S., Gardner G.J., Nguyen P., Choi Y.-H., Trepel J.B.,
RA   Auersperg N., Birrer M.J.;
RT   "CL100 expression is down-regulated in advanced epithelial ovarian
RT   cancer and its re-expression decreases its malignant potential.";
RL   Oncogene 21:4435-4447(2002).
//
RX   PubMed=17254797; DOI=10.1016/j.biologicals.2006.10.001;
RA   Azari S., Ahmadi N., Jeddi-Tehrani M., Shokri F.;
RT   "Profiling and authentication of human cell lines using short tandem
RT   repeat (STR) loci: report from the National Cell Bank of Iran.";
RL   Biologicals 35:195-202(2007).
//
RX   PubMed=19926575; DOI=10.1309/AJCPTK87EMMIKPFS;
RA   DeRycke M.S., Andersen J.D., Harrington K.M., Pambuccian S.E.,
RA   Kalloger S.E., Boylan K.L.M., Argenta P.A., Skubitz A.P.N.;
RT   "S100A1 expression in ovarian and endometrial endometrioid carcinomas
RT   is a prognostic indicator of relapse-free survival.";
RL   Am. J. Clin. Pathol. 132:846-856(2009).
//
RX   PubMed=27561551; DOI=10.1038/ncomms12645;
RA   Coscia F., Watters K.M., Curtis M., Eckert M.A., Chiang C.-Y.,
RA   Tyanova S., Montag A., Lastra R.R., Lengyel E., Mann M.;
RT   "Integrative proteomic profiling of ovarian cancer cell lines reveals
RT   precursor cell associated proteins and functional status.";
RL   Nat. Commun. 7:12645.1-12645.14(2016).
//
RX   PubMed=28196595; DOI=10.1016/j.ccell.2017.01.005;
RA   Li J., Zhao W., Akbani R., Liu W.-B., Ju Z.-L., Ling S.-Y., Vellano C.P.,
RA   Roebuck P., Yu Q.-H., Eterovic A.K., Byers L.A., Davies M.A., Deng W.-L.,
RA   Gopal Y.N.V., Chen G., von Euw E.M., Slamon D.J., Conklin D.,
RA   Heymach J.V., Gazdar A.F., Minna J.D., Myers J.N., Lu Y.-L., Mills G.B.,
RA   Liang H.;
RT   "Characterization of human cancer cell lines by reverse-phase protein
RT   arrays.";
RL   Cancer Cell 31:225-239(2017).
//
RX   PubMed=28546799; DOI=10.1186/s12014-017-9155-z;
RA   Zhao R., Qin W.-J., Qin R.-H., Han J., Li C., Wang Y.-S., Xu C.-J.;
RT   "Lectin array and glycogene expression analyses of ovarian cancer cell
RT   line A2780 and its cisplatin-resistant derivate cell line A2780-cp.";
RL   Clin. Proteomics 14:20.1-20.10(2017).
//